160 related articles for article (PubMed ID: 29181687)
1. miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
Li T; Zhang Y; Meng YP; Bo LS; Ke WB
Pharm Res; 2017 Dec; 34(12):2710-2719. PubMed ID: 29181687
[TBL] [Abstract][Full Text] [Related]
2. Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Yang YC; Cai J; Yin J; Zhang J; Wang KL; Zhang ZT
Carbohydr Polym; 2016 Jan; 136():782-90. PubMed ID: 26572413
[TBL] [Abstract][Full Text] [Related]
3. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Ishijima N; Kanki K; Shimizu H; Shiota G
Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
[TBL] [Abstract][Full Text] [Related]
4. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Wang Z; Zhao K; Zhang Y; Duan X; Zhao Y
Pharm Res; 2019 Aug; 36(10):145. PubMed ID: 31396764
[TBL] [Abstract][Full Text] [Related]
5. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Tom G; Philip S; Isaac R; Praseetha PK; Jiji SG; Asha VV
Life Sci; 2018 Aug; 206():10-21. PubMed ID: 29709652
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
8. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
Zhang Z; Niu B; Chen J; He X; Bao X; Zhu J; Yu H; Li Y
Biomaterials; 2014 May; 35(15):4565-72. PubMed ID: 24602567
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.
Kim HM; Kim SA; Park SB; Cho JH; Song SY
Scand J Gastroenterol; 2017 May; 52(5):577-584. PubMed ID: 28110575
[TBL] [Abstract][Full Text] [Related]
10. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
11. PEG-PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations.
Li Y; Qi XR; Maitani Y; Nagai T
Nanotechnology; 2009 Feb; 20(5):055106. PubMed ID: 19417337
[TBL] [Abstract][Full Text] [Related]
12. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
[TBL] [Abstract][Full Text] [Related]
14. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
Zhao ZB; Long J; Zhao YY; Yang JB; Jiang W; Liu QZ; Yan K; Li L; Wang YC; Lian ZX
Biomater Sci; 2018 Mar; 6(4):893-900. PubMed ID: 29512660
[TBL] [Abstract][Full Text] [Related]
15. Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC).
Rajasekaran D; Srivastava J; Ebeid K; Gredler R; Akiel M; Jariwala N; Robertson CL; Shen XN; Siddiq A; Fisher PB; Salem AK; Sarkar D
Bioconjug Chem; 2015 Aug; 26(8):1651-61. PubMed ID: 26079152
[TBL] [Abstract][Full Text] [Related]
16. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Li YJ; Dong M; Kong FM; Zhou JP
Int J Pharm; 2015 Jul; 489(1-2):83-90. PubMed ID: 25888801
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Vaira V; Roncalli M; Carnaghi C; Faversani A; Maggioni M; Augello C; Rimassa L; Pressiani T; Spagnuolo G; Di Tommaso L; Fagiuoli S; Rota Caremoli E; Barberis M; Labianca R; Santoro A; Bosari S
Liver Int; 2015 Mar; 35(3):1077-86. PubMed ID: 25040368
[TBL] [Abstract][Full Text] [Related]
18. Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells.
Gui K; Zhang X; Chen F; Ge Z; Zhang S; Qi X; Sun J; Yu Z
Biomed Pharmacother; 2019 Mar; 111():751-764. PubMed ID: 30612000
[TBL] [Abstract][Full Text] [Related]
19. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
